Actinic Keratosis Market 2028

DelveInsight's 'Actinic Keratosis - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Actinic Keratosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Actinic Keratosis from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2016-2028


Actinic Keratosis - Disease Understanding and Treatment Algorithm

Actinic keratosis (AK) is a chronic and prevalent disease affecting areas of sun-exposed skin where visible and subclinical, non-visible lesions coexist. This area of sun-damaged skin is prone to the development of further visible AK lesions and sun related skin cancer and is known by many as 'field cancerization'. There are several different clinical variants of AK, such as Classic, Hypertrophic or hyperkeratotic, Proliferative, AK with cutaneous horn, Actinic Chelitis, Pigmented AK and Bowenoid AK.

The DelveInsight Actinic Keratosis market report gives the thorough understanding of the Actinic Keratosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Actinic Keratosis in the US, Europe, and Japan.


Actinic Keratosis Epidemiology

The Actinic Keratosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population, Sex-Specific Prevalent Population and Total Diagnosed Prevalent Population] scenario of Actinic Keratosis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

Actinic Keratosis is more prevalent among male than female population. DelveInsight estimates, the male-to-female ratios of AK patients differ among various countries, but a male excess is a consistent finding among all countries except Italy. According to DelveInsight's analysts, prevalent population of Actinic Keratosis in 7MM countries is expected to increase at a CAGR of 0.85% for the study period [2016-2028].


Actinic Keratosis Drug Chapters

This segment of the Actinic Keratosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The therapeutic landscape of Actinic Keratosis is segmented widely into three main therapies that include the lesion directed Destructive Therapies (cryosurgery, curettage, laser, dermabrasion, surgery etc.), field directed Topical Therapies (imiquimod, ingenol mebutate, 5-fluorouracil, and others) and Photodynamic therapies (such as Levulan Kerastick, Metvixia cream). Detailed chapters of upcoming therapies such as KX-01 (Athenex), VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma) and SOR 007 (DFB Soria) which are expected to launch during the forecast period [2019-2028] have also been covered in the report.


Actinic Keratosis Market Outlook

The Actinic Keratosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Among the three class therapies, Destructive Therapy is the most prescribed, that leads to highest market size, followed by Topical Therapies. According to DelveInsight, the market size of Actinic Keratosis in the seven major markets was approximately USD 4.6 billion in 2016. Among the EU5 countries, the Germany had the highest market size with ~USD 0.3 billion in 2016, while Spain had the lowest market size of Actinic Keratosis with USD 0.11 billion in 2016.


Actinic Keratosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of Topical therapies for Actinic Keratosis such as KX-01 (Athenex), VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma) and SOR 007 (DFB Soria) in the forecast period [2019-2028] will also create a positive impact on the Actinic Keratosis market.


Actinic Keratosis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Actinic Keratosis Report Key Strengths

• 10 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Market Size by Therapies

• Drugs Uptake


Actinic Keratosis Report Assessment

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Actinic Keratosis market

• Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis market

• To understand the future market competition in the Actinic Keratosis market.

1.           Key Insights


2.           Actinic Keratosis: Market Overview at a Glance


2.1.        Total Market Share (%) Distribution of Actinic Keratosis in 2016


2.2.        Total Market Share (%) Distribution of Actinic Keratosis in 2028


2.3.        Total Market Share (%) Distribution by therapies in 2016


2.4.        Total Market Share (%) Distribution by therapies in 2028


3.           Disease Background and Overview


3.1.        Introduction


3.2.        Signs and Symptoms


3.3.        Classification Systems


3.4.        Clinical variants of Actinic Keratosis


3.5.        Pathophysiology


3.6.        Genetic Basis of Actinic Keratosis


3.7.        Causes and Risk factors for Actinic Keratosis


3.8.        Diagnosis


4.           Epidemiology and Patient Population


4.1.        Key Findings


4.2.        7MM Total Prevalent Patient Population of Actinic Keratosis


5.           Country Wise-Epidemiology of Actinic Keratosis Disease


5.1.        United States


5.1.1.    Assumptions and Rationale


5.1.2.    Total Prevalent Population of Actinic Keratosis in the United States


5.1.3.    Sex-Specific Prevalent Population of Actinic Keratosis in the United States


5.1.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in the United States


5.2.        EU5 Countries


5.3.        Germany


5.3.1.    Assumptions and Rationale


5.3.2.    Total Prevalent Population of Actinic Keratosis in Germany


5.3.3.    Sex-Specific Prevalent Population of Actinic Keratosis in Germany


5.3.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in Germany


5.4.        France


5.4.1.    Assumptions and Rationale


5.4.2.    Total Prevalent Population of Actinic Keratosis in France


5.4.3.    Sex-Specific Prevalent Population of Actinic Keratosis in France


5.4.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in France


5.5.        Italy


5.5.1.    Assumptions and Rationale


5.5.2.    Total Prevalent Population of Actinic Keratosis in Italy


5.5.3.    Sex-Specific Prevalent Population of Actinic Keratosis in Italy


5.5.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in Italy


5.6.        Spain


5.6.1.    Assumptions and Rationale


5.6.2.    Total Prevalent Population of Actinic Keratosis in Spain


5.6.3.    Sex-Specific Prevalent Population of Actinic Keratosis in Spain


5.6.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in Spain


5.7.        United Kingdom


5.7.1.    Assumptions and Rationale


5.7.2.    Total Prevalent Population of Actinic Keratosis in the United Kingdom


5.7.3.    Sex-Specific Prevalent Population of Actinic Keratosis in the United Kingdom


5.7.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in the United Kingdom


5.8.        Japan


5.8.1.    Assumptions and Rationale


5.8.2.    Total Prevalent Population of Actinic Keratosis in Japan


5.8.3.    Sex-Specific Prevalent Population of Actinic Keratosis in Japan


5.8.4.    Total Diagnosed Prevalent Population of Actinic Keratosis in Japan


6.           Treatment Practices


6.1.        Treatment goals


6.2.        Lesion-Directed Therapies: First line treatment


6.3.        Field-Directed Therapies: Topical therapies


6.4.        Photodynamic therapy


6.5.        British Association of Dermatologists Guidelines for the care of patients with actinic keratosis 2017


6.6.        Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis


7.           Current Unmet Needs


8.           Marketed Drugs


8.1.        Aldara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)


8.1.1.    Drug Description


8.1.2.    Mechanism of Action


8.1.3.    Regulatory Milestones


8.1.4.    Advantages & Disadvantages


8.1.5.    Safety and Efficacy of Aldara


8.1.6.    Product Profile


8.2.        Zyclara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)


8.2.1.    Drug Description


8.2.2.    Mechanism of Action


8.2.3.    Regulatory Milestones


8.2.4.    Advantages & Disadvantages


8.2.5.    Safety and Efficacy of Zyclara


8.2.6.    Product Profile


8.3.        Solaraze: Sandoz Pharmaceuticals


8.3.1.    Drug Description


8.3.2.    Regulatory Milestones


8.3.3.    Advantages & Disadvantages


8.3.4.    Safety and Efficacy of Solaraze


8.3.5.    Product Profile


8.4.        Efudex: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)


8.4.1.    Drug Description


8.4.2.    Mechanism of Action


8.4.3.    Regulatory Milestones


8.4.4.    Advantages & Disadvantages


8.4.5.    Safety and Efficacy of Efudex


8.4.6.    Product Profile


8.5.        Carac: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)


8.5.1.    Drug Description


8.5.2.    Mechanism of Action


8.5.3.    Regulatory Milestones


8.5.4.    Advantages & Disadvantages


8.5.5.    Safety and Efficacy of Carac


8.5.6.    Product Profile


8.6.        Picato: LEO Pharma


8.6.1.    Drug Description


8.6.2.    Mechanism of action


8.6.3.    Regulatory Milestones


8.6.4.    Advantages & Disadvantages


8.6.5.    Safety and Efficacy of Picato


8.6.6.    Product Profile


8.7.        Actikerell: Almirall S.A.


8.7.1.    Drug Description


8.7.2.    Mechanism of action


8.7.3.    Regulatory Milestones


8.7.4.    Advantages & Disadvantages


8.7.5.    Safety and Efficacy of Actikerell


8.7.6.    Product Profile


8.8.        Fluoroplex: Aqua Pharmaceuticals


8.8.1.    Drug Description


8.8.2.    Mechanism of action


8.8.3.    Regulatory Milestones


8.8.4.    Product Profile


8.9.        Ameluz: Biofrontera


8.9.1.    Drug Description


8.9.2.    Mechanism of action


8.9.3.    Regulatory Milestones


8.9.4.    Advantages & Disadvantages


8.9.5.    Safety and Efficacy of Ameluz


8.9.6.    Product Profile


8.10.     Metvixia: Galderma


8.10.1.  Drug Description


8.10.2.  Mechanism of action


8.10.3.  Regulatory Milestones


8.10.4.  Safety and Efficacy of Metvixia


8.10.5.  Product Profile


8.11.     Levulan Kerastick: DUSA Pharmaceuticals


8.11.1.  Drug Description


8.11.2.  Mechanism of action


8.11.3.  Regulatory Milestones


8.11.4.  Safety and Efficacy


8.11.5.  Product Profile


8.12.     Alacare: Photonamic GmbH & Co. KG


8.12.1.  Drug Description


8.12.2.  Mechanism of action


8.12.3.  Regulatory Milestones


8.12.4.  Advantages & Disadvantages


8.12.5.  Safety and Efficacy of Alacare


8.12.6.  Product Profile


8.13.     Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp


8.13.1.  Drug description


8.13.2.  Mechanism of action


9.           Key Cross Competition


10.         Emerging Drugs


10.1.     LEO 43204: Leo Pharma


10.1.1.  Product Description


10.1.2.  Other Development Activities


10.1.3.  Clinical Development


10.1.4.  Ongoing Trials Information


10.1.5.  Safety and efficacy


10.1.6.  Advantages and Disadvantages


10.1.7.  Product Profile


10.2.     KX01 Ointment: Athenex


10.2.1.  Product Description


10.2.2.  Other Development Activities


10.2.3.  Clinical Development


10.2.4.  Ongoing Trials Information


10.2.5.  Safety and Efficacy


10.2.6.  Advantages and Disadvantages


10.2.7.  Product Profile


10.3.     DFD-07: Promius Pharma


10.3.1.  Product Description


10.3.2.  Clinical Development


10.3.3.  Ongoing Trials Information


10.3.4.  Advantages and Disadvantages


10.3.5.  Product Profile


10.4.     VDA-1102: Vidac Pharma


10.4.1.  Product Description


10.4.2.  Other Developmental Activities


10.4.3.  Clinical Development


10.4.4.  Ongoing Trials Information


10.4.5.  Safety and efficacy


10.4.6.  Advantages and Disadvantages


10.4.7.  Product Profile


10.5.     SOR 007: DFB Soria


10.5.1.  Product Description


10.5.2.  Other development activities


10.5.3.  Clinical Development


10.5.4.  Ongoing Trials Information


10.5.5.  Advantages and Disadvantages


10.5.6.  Product Profile


10.6.     GDC695: Gage Development Company


10.6.1.  Product Description


10.6.2.  Clinical Development


10.6.3.  Ongoing Trials Information


10.6.4.  Product Profile


10.7.     Sotirimod: Mylan


10.7.1.  Product Description


10.7.2.  Other Development Activities


10.7.3.  Product Profile


10.8.     LFX 453: Novartis


10.8.1.  Product Description


10.8.2.  Clinical Development


10.8.3.  Ongoing Trials Information


10.8.4.  Product Profile


10.9.     Ameluz (Daylight-PDT): Biofrontera


10.9.1.  Product Description


10.9.2.  Other development activities


10.9.3.  Clinical Development


10.9.4.  Safety and efficacy


10.9.5.  Product Profile


10.10.   Metvixia: Galderma


10.10.1. Product Description


10.10.2. Clinical Development


10.10.3. Ongoing Trials Information


10.10.4. Safety and efficacy


10.10.5. Product Profile


10.11.   SR-T100 Gel: G&E Herbal Biotechnology


10.11.1. Product Description


10.11.2. Other Development Activities


10.11.3. Clinical Development


10.11.4. Clinical Trials information


10.11.5. Safety and Efficacy


10.11.6. Product Profile


10.12.   Levulan Kerastick and BLU-U PDT: DUSA Pharmaceuticals


10.12.1. Product Description


10.12.2. Other Developmental Activities


10.12.3. Clinical Development


10.12.4. Clinical Trials information


10.12.5. Safety and Efficacy


10.12.6. Product Profile


11.         Actinic Keratosis: 7 Major Market Analysis


11.1.     Key Findings


11.2.     Total Market Size of Actinic Keratosis in 7MM


11.3.     Market Size of Actinic Keratosis by therapies, in 7MM


11.4.     Market Size of Topical Therapies for Actinic Keratosis, in 7MM


12.         The United States Market Outlook of Actinic Keratosis


12.1.     Total Market Size of Actinic Keratosis in the United States


12.2.     Market Size of Actinic Keratosis by therapies, in the United States


12.3.     Market Size of Actinic Keratosis by Topical Therapies, in the United States


13.         EU-5 Countries: Market Outlook


14.         Germany Market outlook of Actinic Keratosis


14.1.     Total Market Size of Actinic Keratosis in Germany


14.2.     Market Size of Actinic Keratosis by therapies, in Germany


14.3.     Market Size of Topical Therapies for Actinic Keratosis, in Germany


15.         France Market outlook of Actinic Keratosis


15.1.     Total Market Size of Actinic Keratosis in France


15.2.     Market Size of Actinic Keratosis by therapies, in France


15.3.     Market Size of Topical Therapies for Actinic Keratosis, in France


16.         Italy Market outlook of Actinic Keratosis


16.1.     Total Market Size of Actinic Keratosis in Italy


16.2.     Market Size of Actinic Keratosis by therapies, in Italy


16.3.     Market Size of Topical Therapies for Actinic Keratosis, in Italy


17.         Spain Market outlook of Actinic Keratosis


17.1.     Total Market Size of Actinic Keratosis in Spain


17.2.     Market Size of Actinic Keratosis by therapies, in Spain


17.3.     Market Size of Topical Therapies for Actinic Keratosis, in Spain


18.         United Kingdom Market outlook of Actinic Keratosis


18.1.     Total Market Size of Actinic Keratosis in United Kingdom


18.2.     Market Size of Actinic Keratosis by therapies, in the United Kingdom


18.3.     Market Size of Topical Therapies for Actinic Keratosis, in the United Kingdom


19.         Japan Market outlook of Actinic Keratosis


19.1.     Total Market Size of Actinic Keratosis in Japan


19.2.     Market Size of Actinic Keratosis by therapies, in Japan


19.3.     Market Size of Topical Therapies for Actinic Keratosis, in Japan


20.         Market Drivers


21.         Market Barriers


22.         Appendix


22.1.     Report Methodology


23.         DelveInsight Capabilities


24.         Disclaimer


25.         About DelveInsight

8.10.3.  Regulatory Milestones


8.10.4.  Safety and Efficacy of Metvixia


8.10.5.  Product Profile


8.11.     Levulan Kerastick: DUSA Pharmaceuticals


8.11.1.  Drug Description


8.11.2.  Mechanism of action


8.11.3.  Regulatory Milestones


8.11.4.  Safety and Efficacy


8.11.5.  Product Profile


8.12.     Alacare: Photonamic GmbH & Co. KG


8.12.1.  Drug Description


8.12.2.  Mechanism of action


8.12.3.  Regulatory Milestones


8.12.4.  Advantages & Disadvantages


8.12.5.  Safety and Efficacy of Alacare


8.12.6.  Product Profile


8.13.     Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp


8.13.1.  Drug description


8.13.2.  Mechanism of action


9.           Key Cross Competition


10.         Emerging Drugs


10.1.     LEO 43204: Leo Pharma


10.1.1.  Product Description


10.1.2.  Other Development Activities


10.1.3.  Clinical Development


10.1.4.  Ongoing Trials Information


10.1.5.  Safety and efficacy


10.1.6.  Advantages and Disadvantages


10.1.7.  Product Profile


10.2.     KX01 Ointment: Athenex


10.2.1.  Product Description


10.2.2.  Other Development Activities


10.2.3.  Clinical Development


10.2.4.  Ongoing Trials Information


10.2.5.  Safety and Efficacy


10.2.6.  Advantages and Disadvantages


10.2.7.  Product Profile


10.3.     DFD-07: Promius Pharma


10.3.1.  Product Description


10.3.2.  Clinical Development


10.3.3.  Ongoing Trials Information


10.3.4.  Advantages and Disadvantages


10.3.5.  Product Profile


10.4.     VDA-1102: Vidac Pharma


10.4.1.  Product Description


10.4.2.  Other Developmental Activities


10.4.3.  Clinical Development


10.4.4.  Ongoing Trials Information


10.4.5.  Safety and efficacy


10.4.6.  Advantages and Disadvantages


10.4.7.  Product Profile


10.5.     SOR 007: DFB Soria


10.5.1.  Product Description


10.5.2.  Other development activities


10.5.3.  Clinical Development


10.5.4.  Ongoing Trials Information


10.5.5.  Advantages and Disadvantages


10.5.6.  Product Profile


10.6.     GDC695: Gage Development Company


10.6.1.  Product Description


10.6.2.  Clinical Development


10.6.3.  Ongoing Trials Information


10.6.4.  Product Profile


10.7.     Sotirimod: Mylan


10.7.1.  Product Description


10.7.2.  Other Development Activities


10.7.3.  Product Profile


10.8.     LFX 453: Novartis


10.8.1.  Product Description


10.8.2.  Clinical Development


10.8.3.  Ongoing Trials Information


10.8.4.  Product Profile


10.9.     Ameluz (Daylight-PDT): Biofrontera


10.9.1.  Product Description


10.9.2.  Other development activities


10.9.3.  Clinical Development


10.9.4.  Safety and efficacy


10.9.5.  Product Profile


10.10.   Metvixia: Galderma


10.10.1. Product Description


10.10.2. Clinical Development


10.10.3. Ongoing Trials Information


10.10.4. Safety and efficacy


10.10.5. Product Profile


10.11.   SR-T100 Gel: G&E Herbal Biotechnology


10.11.1. Product Description


10.11.2. Other Development Activities


10.11.3. Clinical Development


10.11.4. Clinical Trials information


10.11.5. Safety and Efficacy


10.11.6. Product Profile


10.12.   Levulan Kerastick and BLU-U PDT: DUSA Pharmaceuticals


10.12.1. Product Description


10.12.2. Other Developmental Activities


10.12.3. Clinical Development


10.12.4. Clinical Trials information


10.12.5. Safety and Efficacy


10.12.6. Product Profile


11.         Actinic Keratosis: 7 Major Market Analysis


11.1.     Key Findings


11.2.     Total Market Size of Actinic Keratosis in 7MM


11.3.     Market Size of Actinic Keratosis by therapies, in 7MM


11.4.     Market Size of Topical Therapies for Actinic Keratosis, in 7MM


12.         The United States Market Outlook of Actinic Keratosis


12.1.     Total Market Size of Actinic Keratosis in the United States


12.2.     Market Size of Actinic Keratosis by therapies, in the United States


12.3.     Market Size of Actinic Keratosis by Topical Therapies, in the United States


13.         EU-5 Countries: Market Outlook


14.         Germany Market outlook of Actinic Keratosis


14.1.     Total Market Size of Actinic Keratosis in Germany


14.2.     Market Size of Actinic Keratosis by therapies, in Germany


14.3.     Market Size of Topical Therapies for Actinic Keratosis, in Germany


15.         France Market outlook of Actinic Keratosis


15.1.     Total Market Size of Actinic Keratosis in France


15.2.     Market Size of Actinic Keratosis by therapies, in France


15.3.     Market Size of Topical Therapies for Actinic Keratosis, in France


16.         Italy Market outlook of Actinic Keratosis


16.1.     Total Market Size of Actinic Keratosis in Italy


16.2.     Market Size of Actinic Keratosis by therapies, in Italy


16.3.     Market Size of Topical Therapies for Actinic Keratosis, in Italy


17.         Spain Market outlook of Actinic Keratosis


17.1.     Total Market Size of Actinic Keratosis in Spain


17.2.     Market Size of Actinic Keratosis by therapies, in Spain


17.3.     Market Size of Topical Therapies for Actinic Keratosis, in Spain


18.         United Kingdom Market outlook of Actinic Keratosis


18.1.     Total Market Size of Actinic Keratosis in United Kingdom


18.2.     Market Size of Actinic Keratosis by therapies, in the United Kingdom


18.3.     Market Size of Topical Therapies for Actinic Keratosis, in the United Kingdom


19.         Japan Market outlook of Actinic Keratosis


19.1.     Total Market Size of Actinic Keratosis in Japan


19.2.     Market Size of Actinic Keratosis by therapies, in Japan


19.3.     Market Size of Topical Therapies for Actinic Keratosis, in Japan


20.         Market Drivers


21.         Market Barriers


22.         Appendix


22.1.     Report Methodology


23.         DelveInsight Capabilities


24.         Disclaimer


25.         About DelveInsight

Table 1: Clinical variants of Actinic Keratosis Criteria for Grading KIN


Table 2: Reclassification of AK


Table 3: Clinical grading system (according to Olsen 1991)


Table 4: Total Prevalent Population of Actinic Keratosis in the 7MM (2016-2028)


Table 5: Total Prevalent Population of Actinic Keratosis in the United States (2016-2028)


Table 6: Sex Specific Prevalence of Actinic Keratosis in the United States (2016-2028)


Table 7: Diagnosed Prevalence of Actinic Keratosis in the US (2016-2028)


Table 8: Total Prevalent Population of Actinic Keratosis in Germany (2016-2028)


Table 9: Sex Specific Prevalence of Actinic Keratosis in Germany (2016-2028)


Table 10: Total Diagnosed Prevalent Population of Actinic Keratosis in Germany (2016-2028)


Table 11: Total Prevalent Population of Actinic Keratosis in France (2016-2028)


Table 12: Sex Specific Prevalence of Actinic Keratosis in France (2016-2028)


Table 13: Total Diagnosed Prevalent Population of Actinic Keratosis in France (2016-2028)


Table 14: Total Prevalent Population of Actinic Keratosis in Italy (2016-2028)


Table 15: Sex Specific Prevalence of Actinic Keratosis in Italy (2016-2028)


Table 16: Total Diagnosed Prevalent Population of Actinic Keratosis in Italy (2016-2028)


Table 17: Total Prevalent Population of Actinic Keratosis in Spain (2016-2028)


Table 18: Sex Specific Prevalence of Actinic Keratosis in Spain (2016-2028)


Table 19: Total Diagnosed Prevalent Population of Actinic Keratosis in Spain (2016-2028)


Table 20: Total Prevalent Population of Actinic Keratosis in the UK (2016-2028)


Table 21: Sex Specific Prevalence of Actinic Keratosis in the UK (2016-2028)


Table 22: Total Diagnosed Prevalent Population of Actinic Keratosis in the UK (2016-2028)


Table 23: Total Prevalent Population of Actinic Keratosis in Japan (2016-2028)


Table 24: Sex Specific Prevalence of Actinic Keratosis in Japan (2016-2028)


Table 25: Total Diagnosed Prevalent Population of Actinic Keratosis in Japan (2016-2028)


Table 26: Some of Topical Marketed Drugs for Actinic Keratosis


Table 27: 7 Major Market Size of Actinic Keratosis in USD Million (2016-2028)


Table 28: 7 Major Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 29: Market Size of Actinic Keratosis by topical therapies in 7MM, in USD Million (2016-2028)


Table 30: United States Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 31: United States Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 32: United States Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 33: Germany Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 34: Germany Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 35: Germany Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 36: France Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 37: France Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 38: France Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 39: Italy Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 40: Italy Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 41: Italy Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 42: Spain Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 43: Spain Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 44: Spain Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 45: UK Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 46: United Kingdom Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 47: United Kingdom Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Table 48: Japan Market Size of Actinic Keratosis in USD, Million (2016-2028)


Table 49: Japan Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Table 50: Japan Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)

Figure 1: Signs and Symptoms of Actinic Keratosis


Figure 2: Clinical variants of Actinic Keratosis


Figure 3: Causes of Actinic Keratosis


Figure 4: Risk factors for the development of basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs).


Figure 5: Diagnostic Criteria for Actinic Keratosis


Figure 6: Total Prevalent Population of Actinic Keratosis in the 7MM (2016-2028)


Figure 7: Total Prevalent Population of Actinic Keratosis in the United States (2016-2028)


Figure 8: Sex Specific Prevalence of Actinic Keratosis in the United States (2016-2028)


Figure 9: Diagnosed Prevalence of Actinic Keratosis in the United States (2016-2028)


Figure 10: Total Prevalent Population of Actinic Keratosis in Germany (2016-2028)


Figure 11: Sex Specific Prevalence of Actinic Keratosis in Germany (2016-2028)


Figure 12: Total Diagnosed Prevalent Population of Actinic Keratosis in Germany (2016-2028)


Figure 13: Total Prevalent Population of Actinic Keratosis in France (2016-2028)


Figure 14: Sex Specific Prevalence of Actinic Keratosis in France (2016-2028)


Figure 15: Total Diagnosed Prevalent Population of Actinic Keratosis in France (2016-2028)


Figure 16: Total Prevalent Population of Actinic Keratosis in Italy (2016-2028)


Figure 17: Sex Specific Prevalence of Actinic Keratosis in Italy (2016-2028)


Figure 18: Total Diagnosed Prevalent Population of Actinic Keratosis in Italy (2016-2028)


Figure 19: Total Prevalent Population of Actinic Keratosis in Spain (2016-2028)


Figure 20: Sex Specific Prevalence of Actinic Keratosis in Spain (2016-2028)


Figure 21: Total Diagnosed Prevalent Population of Actinic Keratosis in Spain (2016-2028)


Figure 22: Total Prevalent Population of Actinic Keratosis in the UK (2016-2028)


Figure 23: Sex Specific Prevalence of Actinic Keratosis in the United Kingdom (2016-2028)


Figure 24: Total Diagnosed Prevalent Population of Actinic Keratosis in the UK (2016-2028)


Figure 25: Total Prevalent Population of Actinic Keratosis in Japan (2016-2028)


Figure 26: Sex Specific Prevalence of Actinic Keratosis in Japan (2016-2028)


Figure 27: Total Diagnosed Prevalent Population of Actinic Keratosis in Japan (2016-2028)


Figure 28: Proposed algorithm for treatment of Actinic Keratosis.


Figure 29: Actinic Keratosis Therapies Categories


Figure 30: European Medicines Agency Approval Status of Ranked Treatments for AK


Figure 31: Therapies recommended for Actinic Keratosis based on Severity


Figure 32: Treatment Algorithm Based on Expert Consensus


Figure 33: British guidelines for treatment of Actinic Keratosis


Figure 34: Key Recommendations


Figure 35: Overview of the recommendations for the treatment of AK


Figure 36: A practical report and treatment algorithm from AKTeam expert clinicians


Figure 37: Unmet Needs of Actinic Keratosis


Figure 38: Phase III drug analysis


Figure 39: Phase II drug analysis


Figure 40: 7 Major Market Size of Actinic Keratosis in USD Million (2016-2028)


Figure 41: 7 Major Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 42: Market Size of Actinic Keratosis by topical therapies in 7MM, in USD Million (2016-2028)


Figure 43: United States Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 44: United States Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 45: United States Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 46: Germany Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 47: Germany Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 48: Germany Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 49: France Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 50: France Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 51: France Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 52: Italy Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 53: Italy Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 54: Italy Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 55: Spain Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 56: Spain Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 57: Spain Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 58: United Kingdom Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 59: United Kingdom Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 60: United Kingdom Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 61: Japan Market Size of Actinic Keratosis in USD, Million (2016-2028)


Figure 62: Japan Market Size of Actinic Keratosis by therapies, in USD Million (2016-2028)


Figure 63: Japan Market Size of Actinic Keratosis by topical therapies, in USD Million (2016-2028)


Figure 64: Market Drivers


Figure 65: Market Barriers

  • Tags:
  • Actinic Keratosis market
  • Actinic Keratosis market research
  • Actinic Keratosis market insight
  • Actinic Keratosis market trends
  • Actinic Keratosis market forecast
  • Actinic Keratosis market share
  • Actinic Keratosis pipeline drugs
  • Actinic Keratosis treatment algorit...
  • Actinic Keratosis drugs
  • Actinic Keratosis sales forecasting
  • Actinic Keratosis market size
  • Actinic Keratosis disease
  • Actinic Keratosis epidemiology
  • Actinic Keratosis
  • Actinic Keratosis Companies
  • Actinic Keratosis Pipeline

Forward to Friend

Need A Quote